Business
Voyageur Pharmaceuticals Appoints Dr. Iryna Saranchova as Chief Science Officer, Enhancing the Company's Research and Innovation Leadership
(TheNewswire) Calgary, Alberta, Canada, September 17, 2024 – TheNewswire –...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Appoints Dr. Iryna Saranchova as Chief Science Officer, Enhancing the Company's Research and Innovation Leadership\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta, Canada, September 17, 2024 –\n \n\n TheNewswire –\n \n\n Voyageur\nPharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (\"Voyageur\" or\nthe \"Company\") proudly announces the appointment of Dr.\nIryna Saranchova M.D., Ph.D., as its new Chief Science Officer (CSO),\npending regulatory approval. Dr. Saranchova, a distinguished expert in\nclinical research and immunology, brings a wealth of experience that\nwill further accelerate the Company’s scientific endeavors.\n \n\n\n\n With a remarkable career as Chief Clinical Officer at\nMYND Life Sciences, Dr. Saranchova has led ground-breaking research in\nNeuroInflammation, OsteoImmunology, and OncoImmunology. Her leadership\nin developing and implementing clinical studies has set new standards\nwithin the industry, showcasing her ability to foster successful\ncollaborations on a global scale.\n \n\n\n\n Dr. Saranchova has served as an Honorary\nProfessor/Lecturer at the Faculty of Medicine, University of British\nColombia (UBC), and as a Research Fellow at prestigious institutions,\nsuch as the Michael Smith Laboratories and the Vancouver Prostate\nCenter. Her experience spans biomarker discovery, clinical research,\nand the development of immunotherapies.\n \n\n\n\n Dr. Saranchova’s extensive publication portfolio in\nleading scientific journals, including Frontiers in Immunology,\nFrontiers in Pharmacology, and Scientific Reports, highlights her\npioneering work in cancer immunotherapy and immune escape mechanisms\nin metastatic tumors. Her intellectual property portfolio, which\nincludes several cancer related patents, reflects her commitment to\nadvancing healthcare through innovative research and\ndevelopment.\n \n\n\n\n Commenting on her new role, Dr. Saranchova said:\n\"Voyageur's competitively priced imaging products offer the\npotential for global impact, especially in underserved regions, by\nimproving early diagnostics and saving lives. The Royalty Agreement\nwith Rain Cage Inc. (the \"Royalty Agreement\") opens exciting\nopportunities for bringing transformative diagnostic tools and novel\ntreatments to market. ...